Cancer Research AACR Membership Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maloney, E. K.
Right arrow Articles by Singh, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maloney, E. K.
Right arrow Articles by Singh, R.
[Cancer Research 63, 5073-5083, August 15, 2003]
© 2003 American Association for Cancer Research

Regular Articles

An Anti-Insulin-like Growth Factor I Receptor Antibody That Is a Potent Inhibitor of Cancer Cell Proliferation

Erin K. Maloney1, Jennifer L. McLaughlin1, Nancy E. Dagdigian, Lisa M. Garrett, Katherine M. Connors, Xiao-Mai Zhou, Walter A. Blättler, Thomas Chittenden and Rajeeva Singh2

ImmunoGen, Inc., 128 Sidney Street, Cambridge, Massachusetts 02139

An antagonistic monoclonal antibody, designated EM164, has been developed which binds specifically to the human insulin-like growth factor I receptor (IGF-IR) and inhibits the proliferation and survival functions of the receptor in cancer cells. EM164 was initially selected by a rapid cell-based screen of hybridoma supernatants to identify antibodies that bind to IGF-IR but not to the homologous insulin receptor and that show maximal inhibition of IGF-I-stimulated autophosphorylation of IGF-IR. EM164 binds tightly to IGF-IR with a dissociation constant Kd of 0.1 nM, inhibits binding of IGF-I and antagonizes its effects on cells completely, and has no agonistic activity on its own. EM164 inhibits IGF-I-, IGF-II-, and serum-stimulated proliferation and survival of diverse human cancer cell lines in vitro, including breast, lung, colon, cervical, ovarian, pancreatic, melanoma, prostate, neuroblastoma, rhabdomyosarcoma, and osteosarcoma cancer lines. It also suppresses the autocrine or paracrine proliferation of several cancer cell lines. EM164 was the most potent antagonistic anti-IGF-IR antibody tested when compared with several commercially available antibodies. The in vitro inhibitory effect could be extended to in vivo tumor models, where EM164 caused regression of established BxPC-3 human pancreatic tumor xenografts in SCID mice. The antitumor effect of treatment with EM164 could be enhanced by combining it with the cytotoxic agent gemcitabine. These data support the development of EM164 as a candidate therapeutic agent that targets IGF-IR function in cancer cells.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
C. Desbois-Mouthon, A. Baron, M.-J. Blivet-Van Eggelpoel, L. Fartoux, C. Venot, F. Bladt, C. Housset, and O. Rosmorduc
Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma
Clin. Cancer Res., September 1, 2009; 15(17): 5445 - 5456.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Iwasa, I. Okamoto, M. Suzuki, E. Hatashita, Y. Yamada, M. Fukuoka, K. Ono, and K. Nakagawa
Inhibition of Insulin-Like Growth Factor 1 Receptor by CP-751,871 Radiosensitizes Non-Small Cell Lung Cancer Cells
Clin. Cancer Res., August 15, 2009; 15(16): 5117 - 5125.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Shi, R. Lai, Q. Lin, A. S. Iqbal, L. C. Young, L. W. Kwak, R. J. Ford, and H. M. Amin
IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells
Blood, July 9, 2009; 114(2): 360 - 370.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
G. E de Blaquiere, F. E B May, and B. R Westley
Increased expression of both insulin receptor substrates 1 and 2 confers increased sensitivity to IGF-1 stimulated cell migration
Endocr. Relat. Cancer, June 1, 2009; 16(2): 635 - 647.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
U. K. Misra, Y. Mowery, S. Kaczowka, and S. V. Pizzo
Ligation of cancer cell surface GRP78 with antibodies directed against its COOH-terminal domain up-regulates p53 activity and promotes apoptosis
Mol. Cancer Ther., May 1, 2009; 8(5): 1350 - 1362.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Zeng, D. Sachdev, H. Zhang, M. Gaillard-Kelly, and D. Yee
Sequencing of Type I Insulin-Like Growth Factor Receptor Inhibition Affects Chemotherapy Response In vitro and In vivo
Clin. Cancer Res., April 15, 2009; 15(8): 2840 - 2849.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
F. LAUBE
Mannose-6-Phosphate/Insulin-like Growth Factor-II Receptor in Human Melanoma Cells: Effect of Ligands and Antibodies on the Receptor Expression
Anticancer Res, April 1, 2009; 29(4): 1383 - 1388.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. A. Dallas, L. Xia, F. Fan, M. J. Gray, P. Gaur, G. van Buren II, S. Samuel, M. P. Kim, S. J. Lim, and L. M. Ellis
Chemoresistant Colorectal Cancer Cells, the Cancer Stem Cell Phenotype, and Increased Sensitivity to Insulin-like Growth Factor-I Receptor Inhibition
Cancer Res., March 1, 2009; 69(5): 1951 - 1957.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. C. Litzenburger, H.-J. Kim, I. Kuiatse, J. M. Carboni, R. M. Attar, M. M. Gottardis, C. R. Fairchild, and A. V. Lee
BMS-536924 Reverses IGF-IR-Induced Transformation of Mammary Epithelial Cells and Causes Growth Inhibition and Polarization of MCF7 Cells
Clin. Cancer Res., January 1, 2009; 15(1): 226 - 237.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Rodon, V. DeSantos, R. J. Ferry Jr., and R. Kurzrock
Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials
Mol. Cancer Ther., September 1, 2008; 7(9): 2575 - 2588.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Shang, Y. Mao, J. Batson, S. J. Scales, G. Phillips, M. R. Lackner, K. Totpal, S. Williams, J. Yang, Z. Tang, et al.
Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
Mol. Cancer Ther., September 1, 2008; 7(9): 2599 - 2608.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. S. Martins, J. L. Ordonez, A. Garcia-Sanchez, D. Herrero, V. Sevillano, D. Osuna, C. Mackintosh, G. Caballero, A. P. Otero, C. Poremba, et al.
A Pivotal Role for Heat Shock Protein 90 in Ewing Sarcoma Resistance to Anti-Insulin-like Growth Factor 1 Receptor Treatment: In vitro and In vivo Study
Cancer Res., August 1, 2008; 68(15): 6260 - 6270.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Q. Lacy, M. Alsina, R. Fonseca, M. L. Paccagnella, C. L. Melvin, D. Yin, A. Sharma, M. Enriquez Sarano, M. Pollak, S. Jagannath, et al.
Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti-Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma
J. Clin. Oncol., July 1, 2008; 26(19): 3196 - 3203.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. A. Greenberg, S. Somme, H. E. Russnes, A. D. Durbin, and D. Malkin
The Estrogen Receptor Pathway in Rhabdomyosarcoma: A Role for Estrogen Receptor-{beta} in Proliferation and Response to the Antiestrogen 4'OH-Tamoxifen
Cancer Res., May 1, 2008; 68(9): 3476 - 3485.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
D. Sachdev and D. Yee
Disrupting Insulin-Like Growth Factor Signaling as a Potential Cancer Therapy
Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 39 - 58.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. Pos, Z. Wiener, P. Pocza, M. Racz, S. Toth, Z. Darvas, V. Molnar, H. Hegyesi, and A. Falus
Histamine Suppresses Fibulin-5 and Insulin-like Growth Factor-II Receptor Expression in Melanoma
Cancer Res., March 15, 2008; 68(6): 1997 - 2005.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
T. G. Harris, R. D. Burk, H. Yu, H. Minkoff, L. S. Massad, D. H. Watts, Y. Zhong, S. Gange, R. C. Kaplan, K. Anastos, et al.
Insulin-Like Growth Factor Axis and Oncogenic Human Papillomavirus Natural History
Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 245 - 248.
[Abstract] [Full Text] [PDF]

Home page
 J BiochemHome page
Y. Kusada, T. Morizono, A. Matsumoto-Takasaki, K. Sakai, S. Sato, H. Asanuma, A. Takayanagi, and Y. Fujita-Yamaguchi
Construction and Characterization of Single-chain Antibodies Against Human Insulin-like Growth Factor-I Receptor from Hybridomas Producing 1H7 or 3B7 Monoclonal Antibody
J. Biochem., January 1, 2008; 143(1): 9 - 19.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. D. Ryan and P. E. Goss
The Emerging Role of the Insulin-Like Growth Factor Pathway as a Therapeutic Target in Cancer
Oncologist, January 1, 2008; 13(1): 16 - 24.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Peng, Y. Sohara, R. A. Moats, M. D. Nelson Jr., S. G. Groshen, W. Ye, C. P. Reynolds, and Y. A. DeClerck
The Activity of Zoledronic Acid on Neuroblastoma Bone Metastasis Involves Inhibition of Osteoclasts and Tumor Cell Survival and Proliferation
Cancer Res., October 1, 2007; 67(19): 9346 - 9355.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Q.-s. Ji, M. J. Mulvihill, M. Rosenfeld-Franklin, A. Cooke, L. Feng, G. Mak, M. O'Connor, Y. Yao, C. Pirritt, E. Buck, et al.
A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo
Mol. Cancer Ther., August 1, 2007; 6(8): 2158 - 2167.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Lundholm, U. Korner, L. Gunnebo, P. Sixt-Ammilon, M. Fouladiun, P. Daneryd, and I. Bosaeus
Insulin Treatment in Cancer Cachexia: Effects on Survival, Metabolism, and Physical Functioning
Clin. Cancer Res., May 1, 2007; 13(9): 2699 - 2706.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. W. Allen, C. Saba, E. A. Armstrong, S.-M. Huang, S. Benavente, D. L. Ludwig, D. J. Hicklin, and P. M. Harari
Insulin-like Growth Factor-I Receptor Signaling Blockade Combined with Radiation
Cancer Res., February 1, 2007; 67(3): 1155 - 1162.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. Sachdev and D. Yee
Disrupting insulin-like growth factor signaling as a potential cancer therapy
Mol. Cancer Ther., January 1, 2007; 6(1): 1 - 12.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Tanno, C. Mancini, R. Vitali, M. Mancuso, H. P. McDowell, C. Dominici, and G. Raschella
Down-Regulation of Insulin-Like Growth Factor I Receptor Activity by NVP-AEW541 Has an Antitumor Effect on Neuroblastoma Cells In vitro and In vivo.
Clin. Cancer Res., November 15, 2006; 12(22): 6772 - 6780.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. S. McCampbell, R. R. Broaddus, D. S. Loose, and P. J.A. Davies
Overexpression of the Insulin-Like Growth Factor I Receptor and Activation of the AKT Pathway in Hyperplastic Endometrium.
Clin. Cancer Res., November 1, 2006; 12(21): 6373 - 6378.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. D. Wu, K. Haugk, I. Coleman, L. Woodke, R. Vessella, P. Nelson, R. B. Montgomery, D. L. Ludwig, and S. R. Plymate
Combined In vivo Effect of A12, a Type 1 Insulin-Like Growth Factor Receptor Antibody, and Docetaxel against Prostate Cancer Tumors.
Clin. Cancer Res., October 15, 2006; 12(20): 6153 - 6160.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Descamps, S. Wuilleme-Toumi, V. Trichet, C. Venot, L. Debussche, T. Hercend, M. Collette, N. Robillard, R. Bataille, and M. Amiot
CD45neg but Not CD45pos Human Myeloma Cells Are Sensitive to the Inhibition of IGF-1 Signaling by a Murine Anti-IGF-1R Monoclonal Antibody, mAVE1642
J. Immunol., September 15, 2006; 177(6): 4218 - 4223.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Z. Wang, G. Chakravarty, S. Kim, Y. D. Yazici, M. N. Younes, S. A. Jasser, A. A. Santillan, C. D. Bucana, A. K. El-Naggar, and J. N. Myers
Growth-Inhibitory Effects of Human Anti-Insulin-Like Growth Factor-I Receptor Antibody (A12) in an Orthotopic Nude Mouse Model of Anaplastic Thyroid Carcinoma
Clin. Cancer Res., August 1, 2006; 12(15): 4755 - 4765.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
P. A. Kiely, D. O'Gorman, K. Luong, D. Ron, and R. O'Connor
Insulin-Like Growth Factor I Controls a Mutually Exclusive Association of RACK1 with Protein Phosphatase 2A and {beta}1 Integrin To Promote Cell Migration.
Mol. Cell. Biol., June 1, 2006; 26(11): 4041 - 4051.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. S. Martins, C. Mackintosh, D. H. Martin, M. Campos, T. Hernandez, J.-L. Ordonez, and E. de Alava
Insulin-Like Growth Factor I Receptor Pathway Inhibition by ADW742, Alone or in Combination with Imatinib, Doxorubicin, or Vincristine, Is a Novel Therapeutic Approach in Ewing Tumor.
Clin. Cancer Res., June 1, 2006; 12(11): 3532 - 3540.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
A. F. Hezel, A. C. Kimmelman, B. Z. Stanger, N. Bardeesy, and R. A. DePinho
Genetics and biology of pancreatic ductal adenocarcinoma.
Genes & Dev., May 15, 2006; 20(10): 1218 - 1249.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Sachdev, R. Singh, Y. Fujita-Yamaguchi, and D. Yee
Down-regulation of Insulin Receptor by Antibodies against the Type I Insulin-Like Growth Factor Receptor: Implications for Anti-Insulin-Like Growth Factor Therapy in Breast Cancer
Cancer Res., February 15, 2006; 66(4): 2391 - 2402.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Menu, H. Jernberg-Wiklund, T. Stromberg, H. De Raeve, L. Girnita, O. Larsson, M. Axelson, K. Asosingh, K. Nilsson, B. Van Camp, et al.
Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model
Blood, January 15, 2006; 107(2): 655 - 660.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Feng, Z. Zhu, X. Xiao, V. Choudhry, J. C. Barrett, and D. S. Dimitrov
Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function
Mol. Cancer Ther., January 1, 2006; 5(1): 114 - 120.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. S. Miller and D. Yee
Type I Insulin-like Growth Factor Receptor as a Therapeutic Target in Cancer
Cancer Res., November 15, 2005; 65(22): 10123 - 10127.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Wang, J. Hailey, D. Williams, Y. Wang, P. Lipari, M. Malkowski, X. Wang, L. Xie, G. Li, D. Saha, et al.
Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody
Mol. Cancer Ther., August 1, 2005; 4(8): 1214 - 1221.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Scotlandi, M. C. Manara, G. Nicoletti, P.-L. Lollini, S. Lukas, S. Benini, S. Croci, S. Perdichizzi, D. Zambelli, M. Serra, et al.
Antitumor Activity of the Insulin-Like Growth Factor-I Receptor Kinase Inhibitor NVP-AEW541 in Musculoskeletal Tumors
Cancer Res., May 1, 2005; 65(9): 3868 - 3876.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Miyamoto, M. Nakamura, K. Shitara, K. Nakamura, Y. Ohki, G. Ishii, M. Goya, K. Kodama, T. Sangai, H. Maeda, et al.
Blockade of Paracrine Supply of Insulin-Like Growth Factors Using Neutralizing Antibodies Suppresses the Liver Metastasis of Human Colorectal Cancers
Clin. Cancer Res., May 1, 2005; 11(9): 3494 - 3502.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. D. Wu, A. Odman, L. M. Higgins, K. Haugk, R. Vessella, D. L. Ludwig, and S. R. Plymate
In vivo Effects of the Human Type I Insulin-Like Growth Factor Receptor Antibody A12 on Androgen-Dependent and Androgen-Independent Xenograft Human Prostate Tumors
Clin. Cancer Res., April 15, 2005; 11(8): 3065 - 3074.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
G. Loughran, N. C. Healy, P. A. Kiely, M. Huigsloot, N. L. Kedersha, and R. O'Connor
Mystique Is a New Insulin-like Growth Factor-I-regulated PDZ-LIM Domain Protein That Promotes Cell Attachment and Migration and Suppresses Anchorage-independent Growth
Mol. Biol. Cell, April 1, 2005; 16(4): 1811 - 1822.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. A. Kiely, M. Leahy, D. O'Gorman, and R. O'Connor
RACK1-mediated Integration of Adhesion and Insulin-like Growth Factor I (IGF-I) Signaling and Cell Migration Are Defective in Cells Expressing an IGF-I Receptor Mutated at Tyrosines 1250 and 1251
J. Biol. Chem., March 4, 2005; 280(9): 7624 - 7633.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. D. Cohen, D. A. Baker, C. Soderstrom, G. Tkalcevic, A. M. Rossi, P. E. Miller, M. W. Tengowski, F. Wang, A. Gualberto, J. S. Beebe, et al.
Combination Therapy Enhances the Inhibition of Tumor Growth with the Fully Human Anti-Type 1 Insulin-Like Growth Factor Receptor Monoclonal Antibody CP-751,871
Clin. Cancer Res., March 1, 2005; 11(5): 2063 - 2073.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. S. Warshamana-Greene, J. Litz, E. Buchdunger, C. Garcia-Echeverria, F. Hofmann, and G. W. Krystal
The Insulin-Like Growth Factor-I Receptor Kinase Inhibitor, NVP-ADW742, Sensitizes Small Cell Lung Cancer Cell Lines to the Effects of Chemotherapy
Clin. Cancer Res., February 15, 2005; 11(4): 1563 - 1571.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. H. Ibrahim and D. Yee
Insulin-Like Growth Factor-I and Breast Cancer Therapy
Clin. Cancer Res., January 15, 2005; 11(2): 944s - 950s.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
C. F Singer, G. Hudelist, W. Lamm, R. Mueller, K. Czerwenka, and E. Kubista
Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors
Endocr. Relat. Cancer, December 1, 2004; 11(4): 861 - 869.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Van Den Bossche and C. Van de Wiele
Receptor Imaging in Oncology by Means of Nuclear Medicine: Current Status
J. Clin. Oncol., September 1, 2004; 22(17): 3593 - 3607.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.